DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--

The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction (especially for small to mid-sized CMOs) in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities.

This report, the 2019 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability. We also assess the outlook for the industry. This report is an improvement over previous reports because it utilizes the integration of Dose manufacturing integration into the Publisher's Pharma Intelligence Center to provide deeper analysis of the industry.

This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2019, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

Report Scope

This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (Contract Service Providers Database) this analysis is driven by a proprietary model of the dose manufacturing industry, which is continuously updated and refined. The 7 tables and 14 figures throughout the report illustrate major points and trends.

This report is required reading for:

  • CMO executives and strategic decision-makers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Private equity investors: they can deeper understanding of the dose CMO market and important insight for identifying potential investment targets.

Reasons to Buy

  • What is the geographic reach of Dose CMOs?
  • What are the 2018 revenues generated by Contract dose manufacturing industry?
  • What are the components of revenue change for Contract Dose Manufacturers?
  • What is the breakdown of 2018 revenues by different dosage forms?
  • What are the characteristics of the largest dose CMOs?
  • How did the revenue growth of Contract Dose manufacturers in 2018 compare to Contract API manufacturers? - What is the outlook for the dose CMO industry?
  • What Dose CMO M&A deals occurred in 2018?

List of Tables

Table 1: Summary of CMO Facility Acquisition of Dose Facilities Activity, 2013-2018

Table 2: CMO Acquisitions of Dose Manufacturing Facilities, 2018

Table 3: Dedicated CMO Acquisitions of Companies with Commercial Dose Capabilities, 2018

Table 4: PE Investments in the Dose CMO Industry, 2013-2018

Table 5: Percentage of Commercial Dose Facilities that Offer Other Services, by Revenue Tier

Table 6: Revenue Composition and Strategic Orientation of Leading CMOs, 2018

Table 7: Geographical Reach of Dose CMO Universe, 2018

List of Figures

Figure 1: Geographic Reach of the Dose CMO Universe, 2018

Figure 2: Geographic Distribution of Commercial Dose Facilities, 2018

Figure 3: Geographic Distribution of Commercial Dose Injectable Facilities, 2018

Figure 4: Dose CMO Count by Revenue Tiers, 2018

Figure 5: Dose CMO Market Size by Revenue, 2009-2018

Figure 6: Components of Growth for Dose CMOs, 2017-2018

Figure 7: Dose CMO Dosage Form Revenue Segments in 2018 ($B)

Figure 8: Headquarters Locations of $0-12M Revenue Tier CMOs

Figure 9: Dosage Forms Manufactured for $0-12M Revenue Tier CMOs

Figure 10: Dose CMO Industry Market Share by Company Revenue Tier, 2018

Figure 11: Bio/Pharma Services Sector Performance

Figure 12: Organic Revenue Growth for Public CMOs

Figure 13: Mega Cap Outsourcing Propensity 2008-2018

Figure 14: Outsourcing of Orphan NMEs 2009-2018

For more information about this report visit https://www.researchandmarkets.com/r/qtzo34

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OTHER MANUFACTURING MANUFACTURING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/03/2019 09:26 AM/DISC: 12/03/2019 09:26 AM

Copyright Business Wire 2019.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.